Licensing

Genentech, Inc.– In March 1995, IDEC and Genentech entered into a collaborative agreement for the clinical development and commercialization of IDEC’s anti-CD20 monoclonal antibody, Rituxan® (Rituximab), for the treatment of B-cell (NHL). In November 1995, IDEC, Genentech and Zenyaku Kogyo Co. Ltd. entered into a joint development, supply and license agreement in which Zenyaku received exclusive rights to develop, market and sell Rituxan in Japan and IDEC will receive royalties on sales of Rituxan in Japan. In addition, IDEC and Genentech are co-promoting Rituxan in the United States. Genentech retained commercialization rights throughout the rest of the world, except in Japan. Genentech has granted F. Hoffmann-La Roche exclusive marketing rights outside the United States, and Roche has elected to market Rituxan under the trademark MabThera. In September 1999 Genentech assumed worldwide manufacturing obligations for Rituxan.

Eisai Co., Ltd.– In December 1995, IDEC and Eisai entered into a collaborative development agreement and a license agreement aimed at the development and commercialization of humanized and PRIMATIZED anti-CD40L antibodies. Under the terms of these agreements, Eisai may provide up to $37.5 million in milestone payments and support for research and development, subject to the attainment of certain milestones and satisfaction of other criteria, of which $33.2 million has been recognized through December 31, 2000.

Mitsubishi Pharma Corporation– In October 2001 IDEC entered into an extension of its collaborative agreement with Mitsubishi Pharma Corporation to support clinical development of IDEC-114 in psoriasis. Financial terms of the collaborative agreement are valued at approximately $35 million, subject to the attainment of product development objectives.

Under the terms of the collaborative agreement Mitsubishi Pharma will share in the costs of the clinical development of IDEC-114, and will also conduct parallel clinical trials in psoriasis in Japan. Under the terms of an existing license agreement IDEC has granted Mitsubishi Pharma an exclusive license in Asia to develop and commercialize anti-CD80 (anti-B7) antibody products. Mitsubishi Pharma will pay IDEC royalties on sales of anti-CD80 (anti-B7) antibody products in Mitsubishi Pharma’s exclusive territories.

Seikagaku Corporation– In December 1994, IDEC and Seikagaku entered into a collaborative development agreement and a license agreement aimed at the development and commercialization of therapeutic products based on IDEC’s PRIMATIZED anti-CD23 antibodies. Under the terms of the agreement, Seikagaku may provide up to $26 million in milestone payments and support for research and development, subject to the attainment of certain milestones, of which $19.9 million has been recognized through December 31, 2000.

Schering AG– In June 1999, IDEC and Schering AG entered into a collaboration and licensing agreement and a supply agreement aimed at the development and commercialization of our radioimmunotherapy ZEVALIN. Under the terms of the agreement, Schering AG may provide up to $47.5 million in product development milestone payments and support for research and development, subject to the attainment of product development objectives, of which $28.1 million has been recognized through December 31, 2000. Schering received marketing and distribution rights to ZEVALIN outside the U.S., and IDEC will receive royalties on eventual product sales by Schering AG.

Taisho Pharmaceuticals Co. Ltd. – In June 2000, IDEC announced a collaboration with Taisho aimed at development and commercialization of antibody therapeutics against MIF for the treatment of inflammatory and autoimmune diseases. Under the terms of the agreements, Taisho may provide up to $32.0 million in product development milestone payments and support for research and development, subject to the attainment of product development objectives, of which $6.2 million has been recognized through December 31, 2000. Taisho received exclusive rights in Asia and Europe to develop and market resulting products emerging from the collaboration, and IDEC will receive royalties on eventual product sales by Taisho.

BACK TO TOP